Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc. (IDYA)
Filing Type: Form 8-K (Current Report)
Date of Report: April 24, 2023
Reporting Period: Preliminary financial data for the quarter ended March 31, 2023.
Key Financial Metrics
Liquidity and Cash Position:
- Cash, Cash Equivalents, and Marketable Securities: Approximately $351.2 million as of March 31, 2023.
- Status: Preliminary estimate; quarter-end financial close processes were not yet completed at the time of filing.
Capital Markets Activity (ATM Program):
- Shares Sold (Jan 1, 2023 – Apr 21, 2023): 142,160 shares.
- Weighted Average Sales Price: Approximately $18.38 per share.
- Remaining Capacity: Approximately $61.8 million available under the $90.0 million ATM facility.
Other Metrics:
- Revenue, Profit, Margins, Debt: The filing text does not provide clear values for these metrics.
Material Changes and Outlook
Management Commentary:
- The Company is an emerging growth company.
- The preliminary cash balance is subject to change upon completion of financial statement closing procedures.
- The independent registered public accounting firm (PricewaterhouseCoopers LLP) has not audited or reviewed the preliminary data.
Risks and Contingencies:
- The preliminary financial data does not present all information necessary for a complete understanding of the Company's financial condition.
- Information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the final audited cash, cash equivalents, and marketable securities balance in the upcoming Form 10-Q for the quarter ended March 31, 2023.
- Confirm the total proceeds generated from the ATM program sales between January 1, 2023, and April 21, 2023.
- Review the full quarterly results for revenue, operating expenses, and net loss once the financial close is complete.
- Monitor the remaining capacity of the ATM facility for future capital raising activities.